Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients
Authors:
- Wouter HuysseWHWouter Huysse
- Frédéric LecouvetFLFrédéric Lecouvet
- Paolo CastellucciPCPaolo Castellucci
- Piet OstPOPiet Ost
- Valerie LambrechtVLValerie Lambrecht
- Carlos ArtigasCarlos Artigas
- Marie-Laurence DenisMDMarie-Laurence Denis
- Kathia De ManKMKathia De Man
- Louke DelrueLDLouke Delrue
- Lennart JansLJLennart Jans
- Aurélie De BruyckerABAurélie De Bruycker
- Filip De VosFVFilip De Vos
Open Access
- 17 October 2017
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 7 (4) , 56
Abstract
We compared fluor-18 choline positron emission tomography/computed tomography (PET/CT) and axial skeleton magnetic resonance imaging (MRI) prospectively obtained for the detection of bone metastases in non-castrated patients with biochemically recurrent prostate cancer following primary treatment. PET/CT was performed 45 min post-injection of 3–4 MBq/kg F-18 methyl choline. MRI included T1- and fluid sensitive T2-weighted images of the spine and pelvis. Readers were initially blinded from other results and all scans underwent independent double reading. The best valuable comparator (BVC) defined the metastatic status. On the basis of the BVC, 15 out of 64 patients presented with 24 bone metastases. On a patient level, the sensitivity and specificity of MRI and PET were not significantly different. On a lesion level, the sensitivity of MRI was significantly better compared to PET, and the specificity did not differ significantly. In conclusion, axial MRI is an interesting screening tool for the detection of bone metastases because of its low probability of false negative results. However, F-18 choline PET is a valuable addition as it can overrule false positive MRI results and detect non-axial metastases.Keywords
This publication has 15 references indexed in Scilit:
- Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancerCurrent Opinion in Urology, 2017
- Prevalence and prognosis of low‐volume, oligorecurrent, hormone‐sensitive prostate cancer amenable to lesion ablative therapyBJU International, 2017
- Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2015
- Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialBMC Cancer, 2014
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancerThe Prostate, 2014
- Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?European Urology, 2012
- A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical RecurrenceClinical Oncology, 2010
- Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection StrategiesJournal of Clinical Oncology, 2007
- Oligometastases.Journal of Clinical Oncology, 1995